Skip to content
Calculator
Guide

Eyelash serums: myristoyl pentapeptide-17 vs bimatoprost

Last updated: October 27, 2026 · 9 min read · By the Grey Peptides Editorial Board

Extreme close-up of eyes looking upward with long eyelashes
Photo by Kindel Media on Pexels
Grey Peptides
Grey Peptides Editorial Board
Every status on this page carries the date it was checked. How we work
Key takeaways
  • Bimatoprost 0.03%, sold as Latisse, is FDA-approved to grow eyelashes, with strong randomised-trial evidence and a label that lists real side effects.
  • Myristoyl pentapeptide-17, a peptide lash serums advertise, has no peer-reviewed clinical trial in PubMed.
  • Some cosmetic 'lash serums' contain prostaglandin drugs related to bimatoprost, linked to loss of fat around the eyes, without a prescription or a warning, and their ingredient lists often do not mention them.

The one approved lash drug

Bimatoprost was first approved in the US in 2001, and its eye-drop form, Lumigan, lowers eye pressure 1. A 0.03% solution for lashes was approved as Latisse on December 24, 2008 (NDA 022369) 2. Its current US label indicates it to treat hypotrichosis of the eyelashes, meaning inadequate lashes, by increasing their growth, including length, thickness and darkness. It is applied once nightly with a sterile single-use applicator along the base of the upper lashes, not dropped into the eye 1.

The evidence is strong. In a five-month randomised trial of 278 people, 78.1% on bimatoprost against 18.4% on the vehicle improved by at least one grade on a global eyelash scale at 16 weeks, with significantly greater gains in length, thickness and darkness measured by image analysis; conjunctival redness was the only adverse event significantly more common than with vehicle (randomised trial) 3. A pooled analysis of six randomised, double-masked trials from 2007 to 2012 found overall adverse event rates similar to vehicle in people with ordinary lash thinning, with eye redness, eyelid itching, eyelid darkening and other mostly early effects (pooled trial data) 4. It did not work everywhere: a 2009 randomised study in alopecia areata, published as a letter, reported a lack of efficacy of latanoprost and bimatoprost for lash growth (small randomised study) 5.

How a prostaglandin grows lashes

The Latisse label says the precise mechanism is unknown but that lash growth is believed to come from increasing the percentage of hairs in the anagen, or growth, phase and how long that phase lasts 1. The label also says that when treatment stops, lash growth is expected to return to its pre-treatment level, and that applying it more than once a night will not increase growth 1. The label's pharmacokinetic data, from the glaucoma version dropped into the eye, show blood levels peaking within ten minutes and falling below the limit of detection in most of 15 healthy people within 1.5 hours 1.

Lash loss after chemotherapy and in children

Bimatoprost has also been tested where lash loss has a medical cause. In a one-year trial of 130 people whose lashes thinned after chemotherapy, more responded on bimatoprost than on the vehicle at four months (37.5% against 18.2%) and six months (46.9% against 18.2%), and responder rates reached about 62% to 68% by twelve months when everyone used the drug; eye redness and punctate keratitis were the most common adverse events (randomised trial) 6. In a 71-person trial in children and adolescents, lash prominence improved in 70.8% on bimatoprost against 26.1% on the vehicle, but the benefit was significant in healthy adolescents, not in the subgroups after chemotherapy or with alopecia areata (randomised trial) 7. The label summarises that paediatric study and reports no new safety issues 1. We found no peptide serum tested in either group. For someone whose lashes fell out during cancer treatment, that makes the approved drug the option with trial data behind it, and the decision belongs with their doctors.

What the Latisse label warns about

The label is explicit. Used by people who also take prostaglandin eye drops for high eye pressure, it may reduce their pressure-lowering effect, so they need monitoring. Pigmentation of the eyelids and iris may occur, and iris pigmentation is likely to be permanent. The label also lists hair growth outside the treatment area, intraocular inflammation and macular oedema among the reactions described in its warnings, and gives eye itching, conjunctival redness and skin darkening as the most frequently reported reactions, each in under 4% of patients 1.

Those warnings matter for the rest of this article, because the same family of drugs turns up, unlabelled, in some products sold as cosmetics.

Peptide lash serums: what the evidence shows

Peptide lash serums are cosmetics, sold without a prescription. One ingredient they name is myristoyl pentapeptide-17, a short peptide with a fatty acid (myristic acid) attached; others include biotin-linked peptides such as biotinoyl tripeptide-1.

The evidence for myristoyl pentapeptide-17 itself is, as far as the medical literature goes, absent. We searched PubMed on October 3, 2026, and again on October 27, for the phrase 'myristoyl pentapeptide' in titles and abstracts, and for 'myristoyl' with 'eyelash': both searches returned no records 8. Whatever claims of lash growth are made for it, none rests on a peer-reviewed trial. Evidence grade: none in the peer-reviewed literature.

The closest published study tested a serum combining peptides and glycosaminoglycans in 30 women for 12 weeks, without a control group; two of its three authors worked in the serum maker's medical affairs department. Lash length rose 8.3% on software measurements and satisfaction rose to 84%, with no adverse effects reported (open-label trial, no control) 9. Without a placebo or vehicle group, it cannot separate the serum's effect from conditioning, better imaging or expectation, and it does not say which peptides did what.

Bimatoprost 0.03% (Latisse)Peptide lash serums (e.g. myristoyl pentapeptide-17)
What it isA prostaglandin analogue drugCosmetic ingredients, often with biotin-peptides and conditioners
Regulated asPrescription medicine (FDA-approved)Cosmetic
Best evidenceRandomised, vehicle-controlled trials (78.1% vs 18.4% improved at 16 weeks)One 30-person open trial of a peptide serum; no peer-reviewed trial of myristoyl pentapeptide-17 in PubMed
Known risksEye itching, redness, skin darkening; iris pigmentation (likely permanent); eye pressure effectsNot studied in a published trial; some products have contained prostaglandin analogues

Prostaglandins hidden in 'peptide' serums

Here is the catch. Some lash serums sold as cosmetics contain prostaglandin analogues, chemical relatives of bimatoprost: a 2022 study compared products containing bimatoprost, norbimatoprost, isopropyl cloprostenate, dechloro-dihydroxy-difluoro-ethylcloprostenolamide or methylamido-dihydro-noralfaprostal, and its authors note that the ingredient list customers see often does not mention the prostaglandin at all (case report and photo study) 10. Prostaglandins are what make bimatoprost grow lashes 1, and products like these come without a prescription, a medical label or a warning about eye pressure or pigmentation.

The same 2022 study described a 35-year-old woman who developed thin, darker skin and hollowing around the eyes after ten months of a cosmetic serum containing isopropyl cloprostenate, which reversed six months after stopping. In an informal comparison, five blinded graders scored 15 pairs of manufacturers' own before-and-after photographs: users of prostaglandin-containing lash serums showed significantly more signs of the fat and volume loss around the eyes known from prostaglandin glaucoma drops than users of non-prostaglandin serums or false lashes (case report and graded photographs) 10.

South Korea's drug regulator has tested for them. A 2025 study from its Ministry of Food and Drug Safety developed a method to detect 11 prostaglandin analogues in cosmetics and, applying it to lash serums on the market, found norbimatoprost in one product (laboratory analysis) 11. The full ingredient list is worth reading, but because it may not name the prostaglandin 10, a clean list is not proof.

How to read lash serum claims

Before-and-after photographs come from the seller, and the 2022 study, which graded manufacturers' own photos, still found signs of side effects in them 10. Satisfaction percentages, like the 84% in the open peptide-serum trial, measure how people feel about their lashes, not how much they grew 9. The bimatoprost trials show what a fair test looks like: a vehicle group, masked assessors, a validated grading scale and image measurements, and even then nearly one in five people on the vehicle improved by a grade 3. A lash peptide claim without a vehicle-controlled trial cannot tell you how much of the change was the peptide.

If you want longer lashes

The evidence points in an awkward direction. The product that clearly works, bimatoprost, is a prescription drug whose label lists its side effects and asks people on eye-pressure drops to be monitored 1, and pooled trials found its overall adverse-event rate similar to vehicle in ordinary lash thinning 4. The products marketed as gentle peptide alternatives either have no published evidence or, in some cases, contain unlabelled prostaglandin cousins of the drug, with the side effects and none of the oversight.

A serum that dramatically lengthens lashes in weeks is worth checking for prostaglandin analogues: the names in the 2022 study all contain 'prost' (bimatoprost, norbimatoprost, isopropyl cloprostenate, ethylcloprostenolamide, noralfaprostal), though the study also warns the list may leave them out 10.

Regulatory status, as of October 27, 2026

Bimatoprost 0.03% is FDA-approved, as Latisse, for eyelash hypotrichosis; the current label is version 25 on DailyMed 1. Peptide lash serums are sold as cosmetics, without the clinical testing and labelling an approved drug carries. Our related pages on argireline and copper peptides for skin look at the evidence for other cosmetic peptides.

Questions to ask before using a lash serum

  • Does the ingredient list include bimatoprost, norbimatoprost, isopropyl cloprostenate or another 'prost' ingredient, and if not, is there any independent test of what the product contains?
  • Do I have glaucoma or high eye pressure, or use prostaglandin eye drops? If so, an eye doctor should know before I use any lash product with a prostaglandin.
  • Do I have light-coloured eyes? Iris darkening from prostaglandins is likely to be permanent.
  • What evidence supports the peptide in this serum: a published controlled trial, or the supplier's own data?
  • If I notice hollowing, darker skin or redness around the eyes, should I stop and see a doctor? In the 2022 case, those changes reversed six months after stopping 10.

The bottom line

The lash product with strong evidence is a prescription prostaglandin drug, bimatoprost, whose label spells out its risks. Myristoyl pentapeptide-17, which lash serums advertise, has no peer-reviewed trial. And some cosmetic lash serums contain prostaglandin relatives, often unlisted, linked to fat loss around the eyes. If you want the version that is known to work, ask a doctor about the approved one.

Frequently asked questions

Do peptide lash serums work?

There is no peer-reviewed trial of myristoyl pentapeptide-17. One uncontrolled study of a peptide and glycosaminoglycan serum in 30 women reported longer lashes at 12 weeks.

What is the difference between a peptide lash serum and Latisse?

Latisse is bimatoprost 0.03%, an FDA-approved prostaglandin drug with randomised-trial evidence and labelled side effects. Peptide serums are cosmetics with little or no published evidence.

Can lash serums cause eye problems?

Bimatoprost's label lists redness, itching, skin darkening and iris pigmentation, and a 2022 study linked prostaglandin lash serums to loss of fat around the eyes. Some cosmetic serums contain these ingredients without naming them on the customer-facing list.

How do I know if my lash serum contains a prostaglandin?

Check the ingredient list for bimatoprost, norbimatoprost, isopropyl cloprostenate or other names containing 'prost'. A 2022 study warns the list often does not mention the prostaglandin, so a clean list is not proof.

Is myristoyl pentapeptide-17 safe?

Its safety and effectiveness have not been tested in any peer-reviewed clinical trial in PubMed as of October 27, 2026.

Sources

  1. Allergan. LATISSE (bimatoprost ophthalmic solution) 0.03% prescribing information: Indications and Usage, Dosage and Administration, Warnings and Precautions, Adverse Reactions. DailyMed set 34f83d9d-2c64-463e-8a90-9a460fedfead, version 25, published December 23, 2025; Initial U.S. Approval 2001; sections 2, 5.1-5.8, 6.1, 12.1 and 12.3 re-read October 27, 2026. DailyMed
  2. FDA, Drugs@FDA (openFDA): LATISSE, NDA 022369, original approval December 24, 2008. Read October 27, 2026.
  3. Smith, S., et al. (2012). Eyelash growth in subjects treated with bimatoprost: a multicenter, randomized, double-masked, vehicle-controlled, parallel-group study. J Am Acad Dermatol, 66(5), 801-6. PMID: 21899919
  4. Wirta, D., et al. (2015). Bimatoprost 0.03% for the Treatment of Eyelash Hypotrichosis: A Pooled Safety Analysis of Six Randomized, Double-masked Clinical Trials. J Clin Aesthet Dermatol, 8(7), 17-29. PMID: 26203317
  5. Roseborough, I., et al. (2009). Lack of efficacy of topical latanoprost and bimatoprost ophthalmic solutions in promoting eyelash growth in patients with alopecia areata. J Am Acad Dermatol, 60(4), 705-6. PMID: 19293023
  6. Wirta, D., et al. (2015). Safety and Efficacy of Bimatoprost for Eyelash Growth in Postchemotherapy Subjects. J Clin Aesthet Dermatol, 8(4), 11-20. PMID: 26060513
  7. Borchert, M., et al. (2016). An evaluation of the safety and efficacy of bimatoprost for eyelash growth in pediatric subjects. Clin Ophthalmol, 10, 419-29. PMID: 27022239
  8. Grey Peptides search of PubMed, October 3, 2026, re-run October 27, 2026: the phrase 'myristoyl pentapeptide' in titles and abstracts, and 'myristoyl' in titles with 'eyelash' in titles or abstracts, each returned 0 records.
  9. Fernandez-Gonzalez, P., et al. (2024). Open clinical trial evaluating the efficacy of a novel eyelash growth enhancer with peptides and glycosaminoglycans. J Cosmet Dermatol, 23(6), 2170-2180. PMID: 38572527
  10. Jamison, A., et al. (2022). Do Prostaglandin Analogue Lash Lengtheners Cause Eyelid Fat and Volume Loss? Aesthet Surg J, 42(11), 1241-1249. PMID: 35700523
  11. Han, K. M., et al. (2025). HPLC method for detecting prostaglandin F(2α) analogs in cosmetics: Optimization for chromatographic separation and sample preparation. J Pharm Biomed Anal, 260, 116788. PMID: 40056490

Educational information, not medical advice. Each dose in this guide names its source, an approved label or a published study. None is a recommendation for you. An unapproved compound has no established safe or effective human dose, and products sold for “research use only” are not made or tested for people. Talk to a doctor before acting on anything on this site, including before you start, stop or change any medicine or dose.

All articles

New guides and rule changes, by email

One short email when a peptide's legal status moves — an FDA or PCAC decision, a WADA list change, an enforcement action — plus new guides and tools. At most one a week, and none when nothing changes. The newsletter has not started sending yet: your first email will be its first issue.

We keep your email address and the page you signed up from, nothing else. How it works · Privacy · RSS instead